Correction

Correction for: EpiAge: a next-generation sequencing-based *ELOVL2* epigenetic clock for biological age assessment in saliva and blood across health and disease

David Cheishvili[1,2,3,*], Sonia Do Carmo[4,*], Filippo Caraci[6,7], Margherita Grasso[7], A Claudio Cuello[4,5], Moshe Szyf[1,2]

[1]EpiMedTech Global, Singapore 409051, Singapore
[2]HKG Epitherapeutics Ltd., Hong Kong SAR, China
[3]Gerald Bronfman Department of Oncology, McGill University, Montreal H4A 3T2, Canada
[4]Department of Pharmacology & Therapeutics, McGill University, Montreal H3G 1Y6, Canada
[5]Visiting Professor, Department of Pharmacology, Oxford University, Oxford OX13QT, UK
[6]Department of Drug and Health Sciences, University of Catania, Catania 95125, Italy
[7]Neuropharmacology and Translational Neurosciences Research Unit, Oasi Research Institute-IRCCS, Troina 94018, Italy
*Equal contribution

Correspondence to: Moshe Szyf; **email:** moshe.szyf@epimedtech.com, https://orcid.org/0000-0003-3881-8214

This article has been corrected: The authors recently found that the formula for the EpiAgePublic model shown in the "Development and application of the EpiAgePublic model to investigate biological aging dynamics" section contains a typographical error. Specifically, the coefficient for cg24724428 was incorrectly presented as **−30.44**, whereas the correct value is **+30.44**.

The model calculates beta values using the formula:

$$\left(\beta_{cg16867657} \times 122.70 + \beta_{cg21572722} \times 24.45 + \beta_{cg24724428} \times 30.44 \right) - 42.91.$$

The authors stated that this correction does not affect the experimental outcome or conclusions of the study. The authors sincerely apologize for any inconvenience caused.